Terkko Navigator / Journal of Cystic Fibrosis

Evidence of early increased sialylation of airway mucins and defective mucociliary clearance in CFTR-deficient piglets

News Article

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR m

Infant spirometry as a predictor of lung function at early childhood in cystic fibrosis patients

Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy

Trends in nontuberculous mycobacteria infection in children and young people with cystic fibrosis

Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients

Sputum versus nasopharyngeal samples for the molecular diagnosis of respiratory viral infection in cystic fibrosis: A pilot study

Acute hyperosmolar hyperglycaemic state in cystic fibrosis-related diabetes caused by glucocorticoid and itraconazole interaction

Delayed glucose peak and elevated 1-hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index

Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression

From micro to macro; joining the dots of early CF lung disease

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients

Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosis

Aerosolized lancovutide in adolescents (≥12 years) and adults with cystic fibrosis – a randomized trial

Immune response of polarized cystic fibrosis airway epithelial cells infected with Influenza A virus

Implementation of pediatric home spirometry: potential height bias

Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis

Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis

Dornase alfa and rate of lung function decline in European patients with cystic fibrosis: A retrospective registry cohort study

Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country

First description of cystic fibrosis

The effect of acute maximal exercise on the regional distribution of ventilation using ventilation MRI in CF

The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis

Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry

Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment

Decreased survival in cystic fibrosis patients with a positive screen for depression

Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis

SARS-CoV-2 seroprevalence in a belgian cohort of patients with cystic fibrosis

Attitudes of pain and opioids prescription practices in U.S. cystic fibrosis centers

New therapies for people with CF in the CFTR modulator world

Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis

Heat acclimation improves sweat gland function and lowers sweat sodium concentration in an adult with cystic fibrosis

Barrier to using APRI and GPR as identifiers of cystic fibrosis liver disease

Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis

The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients.

Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants

Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis

DIGEST: Developing innovative gastroenterology specialty training

Citrullination of extracellular histone H3.1 reduces antibacterial activity and exacerbates its proteolytic degradation

Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin

Cystic fibrosis related diabetes: Revisiting the OGTT and alternate screening tests

Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis

Ivacaftor or lumacaftor/ivacaftor treatment does not alter the core CF airway epithelial gene response to rhinovirus

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

Predicting the course of nutrition and lung disease in infants and children with cystic fibrosis

K162E - A rare and uncategorized CFTR variant causing cystic fibrosis

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient

A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes